Invivyd (IVVD) Research & Development (2021 - 2025)
Invivyd posted quarterly Research & Development of $10.0 million for Q4 2025, down 43.9% year-on-year from $17.9 million in Q4 2024, and up 24.88% on a QoQ basis from $8.0 million in Q3 2025.
Invivyd (IVVD) has 5 years of Research & Development data on file, last reported at $10.0 million in Q4 2025.
- For the quarter ending Q4 2025, Research & Development fell 43.9% year-over-year to $10.0 million; the trailing twelve-month figure through Dec 2025 stood at $38.3 million (down 72.09% YoY), and the FY2025 full-year result was $38.3 million, down 72.09% from the prior year.
- Research & Development for Q4 2025 stood at $10.0 million, up from $8.0 million in the prior quarter.
- Across five years, Research & Development topped out at $92.0 million in Q1 2022 and bottomed at $8.0 million in Q3 2025.
- The 5-year median for Research & Development is $30.7 million (2024), against an average of $34.8 million.
- The widest annual swing landed in 2023, when Research & Development surged 212.59%; it then slumped 86.09% in 2025.
- A 5-year view of Research & Development shows it stood at $68.4 million in 2021, then plunged by 70.89% to $19.9 million in 2022, then soared by 212.59% to $62.3 million in 2023, then plunged by 71.24% to $17.9 million in 2024, then sank by 43.9% to $10.0 million in 2025.
- The last three Research & Development figures came in at $10.0 million (Q4 2025), $8.0 million (Q3 2025), and $9.6 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Invivyd | 208.38 Mn | -18.31 Mn | - | 10.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.05 Mn |
| Sep 30, 2025 | 8.05 Mn |
| Jun 30, 2025 | 9.57 Mn |
| Mar 31, 2025 | 10.64 Mn |
| Dec 31, 2024 | 17.91 Mn |
| Sep 30, 2024 | 57.85 Mn |
| Jun 30, 2024 | 30.33 Mn |
| Mar 31, 2024 | 31.16 Mn |
| Dec 31, 2023 | 62.27 Mn |
| Sep 30, 2023 | 25.57 Mn |
| Jun 30, 2023 | 43.62 Mn |
| Mar 31, 2023 | 27.20 Mn |
| Dec 31, 2022 | 19.92 Mn |
| Sep 30, 2022 | 30.13 Mn |
| Jun 30, 2022 | 37.13 Mn |
| Mar 31, 2022 | 92.04 Mn |
| Dec 31, 2021 | 68.43 Mn |
| Sep 30, 2021 | 45.37 Mn |
| Jun 30, 2021 | 35.07 Mn |
| Mar 31, 2021 | 34.03 Mn |